BioXcel Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
BioXcel Therapeutics, Inc. (BTAI) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 8.63 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- BioXcel Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 8.84M shares, a 41.71% increase year-over-year.
- BioXcel Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 6.24M shares, a 582.60% increase year-over-year.
- BioXcel Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 914.00K shares, a 84.42% decline year-over-year.
- BioXcel Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 5.87M shares.
- BioXcel Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 3.64M shares, a 65.36% increase from fiscal 2024.
- BioXcel Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 2.20M shares, a 485.11% increase from fiscal 2023.
- BioXcel Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 376.00K shares.
- BioXcel Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2021 was 4.00M shares, a 5.32% increase from fiscal 2020.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 8.63M shares 10-Q · filed 2026-08-13 | ||||||
| 2026-03-31 | 8.84M shares 10-Q · filed 2026-05-15 | ||||||
| 2025-12-31 | 3.64M shares 10-K · filed 2026-03-27 | ||||||
| 2025-09-30 | 3.64M shares 10-Q · filed 2025-11-12 | ||||||
| 2025-06-30 | 5.96M shares 10-Q · filed 2026-08-13 | ||||||
| 2025-03-31 | 6.24M shares 10-Q · filed 2026-05-15 | ||||||
| 2024-12-31 | 2.20M shares 10-K · filed 2026-03-27 | ||||||
| 2024-09-30 | 1.01M shares 10-Q · filed 2025-11-12 | 16.22M shares 10-Q · filed 2024-11-14 | |||||
| 2024-06-30 | 904.00K shares 10-Q · filed 2025-08-12 | 14.46M shares 10-Q · filed 2024-08-06 | |||||
| 2024-03-31 | 914.00K shares 10-Q · filed 2025-05-12 | 14.62M shares 10-Q · filed 2024-05-09 | |||||
| 2023-12-31 | 376.00K shares 10-K · filed 2025-03-28 | ||||||
| 2023-09-30 | 5.69M shares 10-Q · filed 2024-11-14 | ||||||
| 2023-06-30 | 5.80M shares 10-Q · filed 2024-08-06 | ||||||
| 2023-03-31 | 5.87M shares 10-Q · filed 2024-05-09 | ||||||
| 2021-12-31 | 4.00M shares 10-K · filed 2022-03-11 | ||||||
| 2021-09-30 | 4.15M shares 10-Q · filed 2021-11-10 | ||||||
| 2021-06-30 | 4.04M shares 10-Q · filed 2021-08-10 | ||||||
| 2021-03-31 | 4.07M shares 10-Q · filed 2021-05-10 | ||||||
| 2020-12-31 | 3.80M shares 10-K · filed 2022-03-11 | ||||||
| 2020-09-30 | 3.83M shares 10-Q · filed 2021-11-10 | 3.83M shares 10-Q · filed 2020-11-12 | |||||
| 2020-06-30 | 3.22M shares 10-Q · filed 2020-08-14 | 3.73M shares 10-Q · filed 2021-08-10 | 3.14M shares 10-Q · filed 2020-08-14 | ||||
| 2020-03-31 | 3.06M shares 10-Q · filed 2021-05-10 | 3.09M shares 10-Q · filed 2020-05-12 | |||||
| 2019-12-31 | 3.01M shares 10-K · filed 2020-03-09 | ||||||
| 2019-09-30 | 3.07M shares 10-Q · filed 2019-11-14 | 3.09M shares 10-Q · filed 2020-11-12 | 2.92M shares 10-Q · filed 2019-11-14 | ||||
| 2019-06-30 | 2.92M shares 10-Q · filed 2019-08-06 | 2.84M shares 10-Q · filed 2019-08-06 | |||||
| 2019-03-31 | 2.76M shares 10-Q · filed 2020-05-12 | 2.68M shares 10-Q · filed 2019-05-07 | |||||
| 2018-12-31 | 2.59M shares 10-K · filed 2020-03-09 | ||||||
| 2018-09-30 | 2.68M shares 10-Q · filed 2018-11-09 | 2.53M shares 10-Q · filed 2018-11-09 | |||||
| 2018-06-30 | 2.54M shares 10-Q · filed 2018-08-08 | 2.45M shares 10-Q · filed 2018-08-08 | |||||
| 2018-03-31 | 2.53M shares 10-Q · filed 2019-05-07 | 2.35M shares 10-Q · filed 2018-05-14 | |||||
| 2017-12-31 | 2.31M shares 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |